A new treatment for polycythemia vera: recombinant interferon alfa.

Recombinant interferon alfa, a natural product with growth inhibitory capabilities, has been demonstrated for the first time to have significant therapeutic efficacy in controlling the red cell mass in patients with the myeloproliferative disease polycythemia vera. The starting dose was 3.0 X 10(6) U three times a week, subcutaneously (SC). In three patients the dose required was 5.0 X 10(6), U five times a week, SC. Side effects were easily tolerated. The striking advantage in the use of this drug is its presumed absence of antileukemic effect. Further evaluation is necessary, but the initial responses are encouraging.
AuthorsR T Silver
JournalBlood (Blood) Vol. 76 Issue 4 Pg. 664-5 (Aug 15 1990) ISSN: 0006-4971 [Print] UNITED STATES
PMID2383649 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Interferon Type I
  • Recombinant Proteins
  • Dose-Response Relationship, Drug
  • Female
  • Follow-Up Studies
  • Humans
  • Informed Consent
  • Interferon Type I (adverse effects, therapeutic use)
  • Male
  • Middle Aged
  • Polycythemia Vera (drug therapy, epidemiology, pathology)
  • Recombinant Proteins

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: